4.6 Article

Galactan biosynthesis in Mycobacterium tuberculosis -: Identification of a bifunctional UDP-galactofuranosyltransferase

Journal

JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 276, Issue 28, Pages 26430-26440

Publisher

AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
DOI: 10.1074/jbc.M102022200

Keywords

-

Funding

  1. NIAID NIH HHS [AI-45317, AI-38087, N01-AI-75320, AI-18357] Funding Source: Medline

Ask authors/readers for more resources

The cell wall of Mycobacterium tuberculosis and related genera is unique among prokaryotes, consisting of a covalently bound complex of mycolic acids, D-arabinan and D-galactan, which is linked to peptidoglycan via a special linkage unit consisting of Rhap-(1 -->3)-GlcNAc-P. Information concerning the biosynthesis of this entire polymer is now emerging with the promise of new drug targets against tuberculosis. Accordingly, we have developed a galactosyltransferase assay that utilizes the disaccharide neoglycolipid accepters beta -D-Galf-(1 -->5)-beta -Galf-O-C-10:1 and beta -D-Galf-(1 -->6)-beta -D-Galf-O-C-10:1, with UDP-Gal in conjunction with isolated membranes. Chemical analysis of the subsequent reaction products established that the enzymatically synthesized products contained both beta -D-Galf linkages ((1 -->5) and (1 -->6)) found within the mycobacterial cell, as well as in an alternating (1 -->5) and (1 -->6) fashion consistent with the established structure of the cell wall. Furthermore, through a detailed examination of the M. tuberculosis genome, we have shown that the gene product of Rv3808c, now termed glfT is a novel UDP-galactofuranosyltransferase, This enzyme possesses dual functionality in per forming both (1 -->5) and (1 -->6) galactofuranosyltransferase reactions with the above neoglycolipid accepters, using membranes isolated from the heterologous host Escherichia coli expressing Rv3808c, Thus, at a biochemical and genetic level, the polymerization of the galactan region of the mycolyl-arabinogalactan complex has been defined, allowing the possibility of further studies toward substrate recognition and catalysis and assay development. Ultimately, this may also lead to a more rational approach to drug design to be explored in the context of mycobacterial infections.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available